Acrotech Biopha

MARQIBO

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Acrotech Biopha

Marqibo HCPCS:

J9371

HCPCS Code Descriptor:

Injection, vincristine sulfate liposome, 1 mg

Category:

J Code

Marqibo NDCs:

No actively aligned NDCs found

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Multiple

Route of Administration:

Intravenous

Marqibo CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Marqibo:

MARQIBO is an Oncology drug manufactured by Acrotech Biopha and administered via the Intravenous route of administration. The J Code: J9371 is aligned to the drug MARQIBO.

ACCESS PRICING AND MORE BY REGISTERING

J9371 Added Date:

January 1, 2014

J9371 Effective Date:

January 1, 2014

J9371 Termination Date:

July 1, 2024

We have not yet identified a manufacturer source of Marqibo billing and coding information.
Marqibo patient assistance information can be found through Acrotech Patient Access at the URL: https://acrotechpatientaccess.com/patient-assistance-program/
MARQIBO prescribing information can be found at the link below:
Information regarding MARQIBO’s side effects can be found at MedlinePlus